Track Beyond Air, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Beyond Air, Inc. XAIR Open Beyond Air, Inc. in new tab

0.4810 USD
EPS
-4.47
P/B
0.52
ROE
-240.21
Beta
0.30
Target Price
8.67 USD
Beyond Air, Inc. logo

Beyond Air, Inc.

🧾 Earnings Recap – Q3 2026

Beyond Air reported a remarkable 105% year-over-year revenue increase to $2.2 million, driven by growing adoption of its LungFit PH system, and strategically strengthened its balance sheet through the sale of its NeuroNOS subsidiary.

  • Achieved significant revenue growth, with quarterly revenue reaching $2.2 million, reflecting strong market demand and increased hospital adoption.
  • Over 45 hospitals currently utilize the first-generation LungFit PH system, with customer retention exceeding 90%.
  • Completed the initial sale of LungFit PH to a VA Medical Center, marking a key milestone in expanding the company’s presence in federal healthcare systems.
  • Expanded international distribution, now covering 40 countries, enhancing the company’s global footprint for long-term growth.
  • Preparing for the anticipated FDA approval of the second-generation LungFit PH system, expected to enhance market reach and operational efficiency.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateJune 29, 2026
EPS-4.47
Book Value0.97
Price to Book0.52
Debt/Equity284.71
% Insiders3.650%
Growth
Revenue Growth1.05%
Estimates
Forward P/E-0.30
Forward EPS-1.66
Target Mean Price8.67

DCF Valuation

Tweak assumptions to recompute fair value for Beyond Air, Inc. (XAIR)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Beyond Air, Inc. Logo Beyond Air, Inc. Analysis (XAIR)

United States Health Care Official Website Stock

Is Beyond Air, Inc. a good investment? Beyond Air, Inc. (XAIR) is currently trading at 0.4810 USD. Market analysts have a consensus price target of 8.67 USD. This suggests a potential upside from current levels.

Earnings Schedule: Beyond Air, Inc. is expected to release its next earnings report on June 29, 2026. The market consensus estimate for Forward EPS is -1.66.

Investor FAQ

Does Beyond Air, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Beyond Air, Inc.?

Beyond Air, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be June 29, 2026. The company currently has a trailing EPS of -4.47.

Company Profile

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Exchange Ticker
NMS (United States) XAIR

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
July 14, 2025 0.050000
July 11, 2017 0.010000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion